Alnylam Pharmaceuticals announces Phase 1 study of ALN-AT3, a subcutaneous therapy being tested on patients with hemophilia.
HTRS announces two new clinical fellowship awards in 2016 for MDs or DOs interested in focusing on hemophilia and/or other rare bleeding disorders.
FDA approves Baxalta's ADYNOVATE, a new longer- lasting recombinant factor VIII product for people with hemophilia A.
Study suggests that toddlers first treated with recombinant factor product are more likely to develop an inhibitor.
MASAC issues new recommendation on inhibitor testing and surveillance for patients with hemophilia A and B, based on CDC study findings.
Latest Medscape educational opportunity for healthcare providers is on inhibitor management.
Lynden Prior and Darian Ross are the recipients of the 2015 Josh Gordy Educational Scholarship.
Latest Nurses Guide chapter focuses on factor concentrates and other treatments for patients with hemophilia A or B.
Medscape's latest online education opportunity for providers is on managing patients with hemophilia using extended half-life factor concentrates.
When in doubt, infuse, says a mother with real-life experience, raising a daughter with hemophilia.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car